MX369479B - Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. - Google Patents
Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada.Info
- Publication number
- MX369479B MX369479B MX2015001088A MX2015001088A MX369479B MX 369479 B MX369479 B MX 369479B MX 2015001088 A MX2015001088 A MX 2015001088A MX 2015001088 A MX2015001088 A MX 2015001088A MX 369479 B MX369479 B MX 369479B
- Authority
- MX
- Mexico
- Prior art keywords
- insulinotropic peptide
- liquid formulation
- peptide conjugate
- acting insulinotropic
- long
- Prior art date
Links
- 230000002473 insulinotropic effect Effects 0.000 title abstract 5
- 239000000863 peptide conjugate Substances 0.000 title abstract 4
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- 238000011109 contamination Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 231100001261 hazardous Toxicity 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una formulación líquida de conjugado de péptido insulinotrópico de acción prolongada, que comprende una cantidad farmacéuticamente eficaz del conjugado péptido insulinotrópico de acción prolongada que consiste en un péptido fisiológicamente activo, péptido insulinotrópico, y una región Fc de inmunoglobulina; y un estabilizador libre de albúmina, en donde el estabilizador comprende una solución amortiguadora, un alcohol de azúcar, un tensioactivo no iónico, y un agente isotónico, y un método para preparar la formulación. Para el propósito de prevenir la contaminación microbiana, se puede agregar un conservante. La formulación líquida de la presente invención está libre de albúmina sérica humana y otros factores potencialmente peligrosos para el cuerpo, sin tener riesgo de contaminación viral, y por consiguiente puede proveer una excelente estabilidad de almacenamiento para los conjugados de péptido insulinotrópico a alta concentración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120081476 | 2012-07-25 | ||
PCT/KR2013/006670 WO2014017845A2 (en) | 2012-07-25 | 2013-07-25 | A liquid formulation of long acting insulinotropic peptide conjugate |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015001088A MX2015001088A (es) | 2015-07-06 |
MX369479B true MX369479B (es) | 2019-11-08 |
Family
ID=49997928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001088A MX369479B (es) | 2012-07-25 | 2013-07-25 | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9801950B2 (es) |
EP (1) | EP2877158B1 (es) |
JP (2) | JP6385345B2 (es) |
KR (1) | KR102161177B1 (es) |
CN (2) | CN108125909A (es) |
AR (1) | AR094821A1 (es) |
AU (1) | AU2013293716B2 (es) |
CA (1) | CA2880026C (es) |
ES (1) | ES2759987T3 (es) |
HK (1) | HK1204565A1 (es) |
MX (1) | MX369479B (es) |
PL (1) | PL2877158T3 (es) |
PT (1) | PT2877158T (es) |
RU (1) | RU2671576C2 (es) |
TW (1) | TWI643637B (es) |
WO (1) | WO2014017845A2 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842951B2 (en) | 2010-01-12 | 2020-11-24 | Aerami Therapeutics, Inc. | Liquid insulin formulations and methods relating thereto |
US9180261B2 (en) | 2010-01-12 | 2015-11-10 | Dance Biopharm Inc. | Preservative free insulin formulations and systems and methods for aerosolizing |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN104870009B (zh) | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
KR102385120B1 (ko) * | 2014-03-31 | 2022-04-12 | 한미약품 주식회사 | 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
PL3209319T3 (pl) * | 2014-10-21 | 2021-12-20 | Hexima Limited | Sposób leczenia zakażeń grzybiczych |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
WO2016108586A1 (ko) | 2014-12-30 | 2016-07-07 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
BR112017018060A2 (pt) | 2015-02-25 | 2018-04-10 | Dance Biopharm Inc | formulação de insulina, dose de unidade, e, método de tratar um indivíduo com diabetes melito. |
EP3302450A4 (en) | 2015-06-04 | 2019-01-16 | Antriabio, Inc. | AMINPEGYLATION METHOD FOR THE PRODUCTION OF SITE-SPECIFIC PROTEIN CONJUGATES |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
PE20180449A1 (es) | 2015-06-30 | 2018-03-05 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
KR102429287B1 (ko) * | 2015-12-10 | 2022-08-05 | 가부시끼가이샤 메니콘 | 펩티드 조성물 |
HRP20220995T1 (hr) | 2015-12-31 | 2022-11-11 | Hanmi Pharm. Co., Ltd. | Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore |
TN2018000452A1 (en) | 2016-06-29 | 2020-06-15 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
KR20180033105A (ko) | 2016-09-23 | 2018-04-02 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
EP3604328A4 (en) | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE |
KR20200125590A (ko) * | 2018-01-26 | 2020-11-04 | 제넨테크, 인크. | 조성물 및 사용 방법 |
CN108841007B (zh) * | 2018-06-14 | 2020-12-29 | 江南大学 | 带有羟胺基的艾塞那肽类似物及其应用 |
EP4154870A1 (en) * | 2020-05-22 | 2023-03-29 | Hanmi Pharm. Co., Ltd. | Liquid preparation of long-acting conjugate of glucagon/glp-1/gip trigonal agonist |
CN114053217B (zh) * | 2020-08-03 | 2023-04-18 | 华兰生物工程股份有限公司 | 一种Exendin-4-Fc融合蛋白注射制剂及其制备方法 |
KR20230000682A (ko) | 2021-06-25 | 2023-01-03 | 한미약품 주식회사 | 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US7399489B2 (en) * | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
EP1525889A1 (en) | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
ES2311560T3 (es) * | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
JP2007524592A (ja) * | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
DE602005015257D1 (es) | 2004-12-22 | 2009-08-13 | Lilly Co Eli | |
WO2006076471A2 (en) | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
US8658174B2 (en) | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
ATE524493T1 (de) | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CA2681743A1 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
BRPI0813699B1 (pt) | 2007-07-10 | 2021-06-22 | Eli Lilly And Company | Formulação de proteína de fusão glp-1-fc |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
EP2214700A4 (en) * | 2007-11-02 | 2012-08-22 | Janssen Biotech Inc | HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES |
EP2451437B1 (de) * | 2009-07-06 | 2016-11-02 | Sanofi-Aventis Deutschland GmbH | Wässrige insulinzubereitungen enthaltend methionin |
WO2011090306A2 (en) * | 2010-01-19 | 2011-07-28 | Hanmi Holdings Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
-
2013
- 2013-07-24 AR ARP130102653A patent/AR094821A1/es not_active Application Discontinuation
- 2013-07-25 KR KR1020130087896A patent/KR102161177B1/ko active IP Right Grant
- 2013-07-25 EP EP13823275.6A patent/EP2877158B1/en active Active
- 2013-07-25 CN CN201810001605.0A patent/CN108125909A/zh active Pending
- 2013-07-25 AU AU2013293716A patent/AU2013293716B2/en active Active
- 2013-07-25 PT PT138232756T patent/PT2877158T/pt unknown
- 2013-07-25 RU RU2015104494A patent/RU2671576C2/ru active
- 2013-07-25 PL PL13823275T patent/PL2877158T3/pl unknown
- 2013-07-25 US US14/416,223 patent/US9801950B2/en active Active
- 2013-07-25 ES ES13823275T patent/ES2759987T3/es active Active
- 2013-07-25 CA CA2880026A patent/CA2880026C/en active Active
- 2013-07-25 JP JP2015524183A patent/JP6385345B2/ja active Active
- 2013-07-25 MX MX2015001088A patent/MX369479B/es active IP Right Grant
- 2013-07-25 CN CN201380039383.7A patent/CN104487053B/zh active Active
- 2013-07-25 WO PCT/KR2013/006670 patent/WO2014017845A2/en active Application Filing
- 2013-07-25 TW TW102126621A patent/TWI643637B/zh active
-
2015
- 2015-05-29 HK HK15105128.7A patent/HK1204565A1/xx unknown
-
2018
- 2018-04-18 JP JP2018079998A patent/JP6685343B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013293716B2 (en) | 2018-04-26 |
RU2671576C2 (ru) | 2018-11-02 |
TW201408337A (zh) | 2014-03-01 |
KR102161177B1 (ko) | 2020-09-29 |
CN108125909A (zh) | 2018-06-08 |
RU2015104494A (ru) | 2016-09-20 |
ES2759987T3 (es) | 2020-05-12 |
JP6385345B2 (ja) | 2018-09-05 |
JP6685343B2 (ja) | 2020-04-22 |
MX2015001088A (es) | 2015-07-06 |
EP2877158A4 (en) | 2016-03-23 |
EP2877158A2 (en) | 2015-06-03 |
AR094821A1 (es) | 2015-09-02 |
CA2880026C (en) | 2020-09-01 |
US20150238629A1 (en) | 2015-08-27 |
PL2877158T3 (pl) | 2020-04-30 |
JP2018119006A (ja) | 2018-08-02 |
CA2880026A1 (en) | 2014-01-30 |
CN104487053A (zh) | 2015-04-01 |
EP2877158B1 (en) | 2019-09-11 |
US9801950B2 (en) | 2017-10-31 |
TWI643637B (zh) | 2018-12-11 |
HK1204565A1 (en) | 2015-11-27 |
CN104487053B (zh) | 2018-01-30 |
KR20140018798A (ko) | 2014-02-13 |
PT2877158T (pt) | 2019-12-17 |
WO2014017845A3 (en) | 2014-03-20 |
BR112015001735A2 (pt) | 2021-04-13 |
AU2013293716A1 (en) | 2015-02-19 |
WO2014017845A2 (en) | 2014-01-30 |
JP2015522654A (ja) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369479B (es) | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. | |
MX2015000988A (es) | Formulacion liquida de un conjugado de insulina de accion prolongada. | |
MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
AU2017279583B2 (en) | Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment | |
MX2013004595A (es) | Formulaciones liquidas de un conjugado de alfa interferon de accion prolongada. | |
PH12014502460A1 (en) | Lyophilised and aqueos anti-cd40 antibody formulations | |
WO2012008779A3 (en) | A liquid formulation of long-acting human growth hormone conjugate | |
WO2012076670A3 (en) | Antibody formulation | |
PH12014502778B1 (en) | Antibody formulation | |
MX340463B (es) | Formulaciones liquidas para un conjugado de g-csf de accion prolongada. | |
MY165614A (en) | Formulations of antibody | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
MX2022008949A (es) | Formulacion de anticuerpos estable. | |
TH162100B (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) | |
TH162100A (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) | |
TH125691B (th) | สูตรของแอนดี้บอดี้ | |
RU2013146393A (ru) | Композиция с репаративным, противовирусным, регенерирующим и антиаллергическим действием для лечения аденовирусных инфекций глаз и носоглотки |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |